Cargando…

Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants

The objective of the paper is to assess the cost-effectiveness of targeted respiratory syncytial virus (RSV) prophylaxis based on a validated prediction rule with 1-year time horizon in moderately preterm infants compared to no prophylaxis. Data on health care consumption were derived from a randomi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Blanken, Maarten O., Frederix, Geert W., Nibbelke, Elisabeth E., Koffijberg, Hendrik, Sanders, Elisabeth A. M., Rovers, Maroeska M., Bont, Louis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5748402/ https://www.ncbi.nlm.nih.gov/pubmed/29168012 http://dx.doi.org/10.1007/s00431-017-3046-1

Ejemplares similares

Prospective Validation of a Prognostic Model for Respiratory Syncytial Virus Bronchiolitis in Late Preterm Infants: A Multicenter Birth Cohort Study
por: Blanken, Maarten O., et al.
Publicado: (2013)

Effectiveness of palivizumab immunoprophylaxis in preterm infants against respiratory syncytial virus disease in Qatar
por: Abushahin, Ahmad, et al.
Publicado: (2018)

Respiratory Syncytial Virus Disease: Immunoprophylaxis Policy Review and Public Health Concerns in Preterm and Young Infants
por: Staebler, Suzanne, et al.
Publicado: (2020)

Respiratory Syncytial Virus Disease in Preterm Infants in the US Born at 32–35 Weeks Gestation Not Receiving Immunoprophylaxis
por: Ambrose, Christopher S., et al.
Publicado: (2014)

Respiratory syncytial virus hospitalizations in US preterm infants after the 2014 change in immunoprophylaxis guidance by the American Academy of Pediatrics
por: Krilov, Leonard R., et al.
Publicado: (2020)

Immunoprophylaxis of respiratory syncytial virus: global experience
por: Simoes, Eric AF
Publicado: (2002)

Patient equity and respiratory syncytial virus Immunoprophylaxis
por: Cody Meissner, H.
Publicado: (2019)

Seasonality in Respiratory Syncytial Virus Hospitalizations and Immunoprophylaxis
por: Kusma, Jennifer D., et al.
Publicado: (2023)

Should we use Palivizumab immunoprophylaxis for infants against respiratory syncytial virus? – a cost-utility analysis
por: Ginsberg, Gary M., et al.
Publicado: (2018)

The effect of high dose inhaled corticosteroids on wheeze in infants after respiratory syncytial virus infection: randomised double blind placebo controlled trial
por: Ermers, Marieke J J, et al.
Publicado: (2009)

743. Severity and Costs of Respiratory Syncytial Virus and Bronchiolitis Hospitalization in Commercially Insured Preterm and Term Infants Before and After the 2014 American Academy of Pediatrics Guidance Change on Immunoprophylaxis
por: Krilov, Leonard R, et al.
Publicado: (2018)

The 2014–2015 National Impact of the 2014 American Academy of Pediatrics Guidance for Respiratory Syncytial Virus Immunoprophylaxis on Preterm Infants Born in the United States
por: Kong, Amanda M., et al.
Publicado: (2018)

Immunoprophylaxis against respiratory syncytial virus with palvizumab: what is new?
por: Sáfadi, Marco Aurélio P.
Publicado: (2014)

Respiratory Syncytial Virus Hospitalizations among U.S. Preterm Infants Compared with Term Infants Before and After the 2014 American Academy of Pediatrics Guidance on Immunoprophylaxis: 2012–2016
por: Goldstein, Mitchell, et al.
Publicado: (2018)

Update on respiratory syncytial virus hospitalizations among U.S. preterm and term infants before and after the 2014 American Academy of Pediatrics policy on immunoprophylaxis: 2011-2017
por: Fergie, Jaime, et al.
Publicado: (2020)

Increased Risk of Wheeze and Decreased Lung Function after Respiratory Syncytial Virus Infection
por: Zomer-Kooijker, Kim, et al.
Publicado: (2014)

Cost-analysis of Withdrawing Immunoprophylaxis for Respiratory Syncytial Virus in Infants Born at 33–35 Weeks Gestational Age in Quebec: A Multicenter Retrospective Study
por: Papenburg, Jesse, et al.
Publicado: (2020)

Passive Immunoprophylaxis against Respiratory Syncytial Virus in Children: Where Are We Now?
por: Rocca, Alessandro, et al.
Publicado: (2021)

The epidemiology and risk factors of respiratory syncytial virus and its impact on the timing of immunoprophylaxis
por: Jeena, Prakash Mohan
Publicado: (2018)

Respiratory-syncytial virus immunoprophylaxis on asthma symptoms development in prematurity with bronchopulmonary dysplasia
por: Fang, Li-Ching, et al.
Publicado: (2023)

The Logistics and Coordination of Respiratory Syncytial Virus Immunoprophylaxis Use Among US Pediatric Specialists
por: Wong, Pierre C., et al.
Publicado: (2016)

Respiratory syncytial virus hospitalization outcomes and costs of full-term and preterm infants
por: McLaurin, K K, et al.
Publicado: (2016)

Assessing Variation in the Cost of Palivizumab for Respiratory Syncytial Virus Prevention in Preterm Infants
por: Shahabi, Ahva, et al.
Publicado: (2017)

Molecular characterization of respiratory syncytial viruses infecting children reported to have received palivizumab immunoprophylaxis
por: Oliveira, Danielle B.L., et al.
Publicado: (2015)

Respiratory Syncytial Virus Immunoprophylaxis with Palivizumab: 12-Year Observational Study of Usage and Outcomes in Canada
por: Mitchell, Ian, et al.
Publicado: (2021)

Vectored immunoprophylaxis: an emerging adjunct to traditional vaccination
por: Sanders, John W., et al.
Publicado: (2017)

Burden of Severe Respiratory Syncytial Virus Disease Among 33–35 Weeks’ Gestational Age Infants Born During Multiple Respiratory Syncytial Virus Seasons
por: Anderson, Evan J., et al.
Publicado: (2017)

Indications to respiratory syncytial virus immunoprophylaxis in the 29–32 wGA group: is there still room for debating?
por: Zuccotti, Gianvincenzo, et al.
Publicado: (2017)

Epidemiology of Respiratory Syncytial Virus Infection in Preterm Infants
por: Resch, Bernhard, et al.
Publicado: (2011)

Effectiveness of palivizumab immunoprophylaxis to prevent respiratory syncytial virus hospitalizations in healthy full-term <6-month-old infants from the circumpolar region of Nunavik, Quebec, Canada
por: Gilca, Rodica, et al.
Publicado: (2020)

Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Preterm Infants Without Chronic Lung Disease or Congenital Heart Disease
por: Figueras-Aloy, Josep, et al.
Publicado: (2016)

Passive Broad-Spectrum Influenza Immunoprophylaxis
por: Berry, Cassandra M., et al.
Publicado: (2014)

AAV Vectored Immunoprophylaxis for Filovirus Infections
por: Rghei, Amira D., et al.
Publicado: (2020)

Palivizumab immunoprophylaxis for infants with BPD has medium- and long-term benefits: myth or maxim?
por: Quinn, Lauren A., et al.
Publicado: (2021)

Risk scoring tool to predict respiratory syncytial virus hospitalisation in premature infants
por: Blanken, Maarten O., et al.
Publicado: (2018)

Emerging Use of Early Health Technology Assessment in Medical Product Development: A Scoping Review of the Literature
por: IJzerman, Maarten J., et al.
Publicado: (2017)

Respiratory Syncytial Virus Hospitalizations in Healthy Preterm Infants: Systematic Review
por: Mauskopf, Josephine, et al.
Publicado: (2016)

Incidence of respiratory syncytial virus infection in children with congenital heart disease undergoing immunoprophylaxis with palivizumab in Pará state, north region of Brazil
por: de Souza, Roseane Porfírio, et al.
Publicado: (2019)

Universal infant immunisation against respiratory syncytial virus and European inequalities: the pandemics lesson has not been learnt
por: De Luca, Daniele, et al.
Publicado: (2023)

Development in Immunoprophylaxis against Rabies for Animals and Humans
por: Nandi, Sukdeb, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_8t8o1j6vedec9c7cfs47mim3bd